Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. [External. gamma. radiation and intracavitary cesium, cobalt or radium]

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
In a prospective study by the Gynecologic Oncology Group (GOG), 104 evaluable patients with cervical squamous cell carcinoma Stages IIIB and IVA were randomly assigned to treatment with hydroxyurea or placebo in combination with radiation. There were no deaths resulting from the treatment. Hematologic toxicity was more common and more severe in patients who received hydroxyurea. Response was evaluated in terms of complete tumor regression, duration of progression-free interval, and survival probability. By all those parameters the response was significantly better in the groups of patients receiving hydroxyurea.
OSTI ID:
6210259
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 5:3; ISSN IOBPD
Country of Publication:
United States
Language:
English

Similar Records

Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. [Radium isotopes]
Conference · Sat Oct 15 00:00:00 EDT 1977 · Am. J. Obstet. Gynecol.; (United States) · OSTI ID:5333410

High Dose-Rate Intracavitary Brachytherapy for Cervical Carcinomas With Lower Vaginal Infiltration
Journal Article · Wed Nov 14 23:00:00 EST 2007 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21039629

Hydroxyurea: a radiation potentiator in carcinoma of the uterine cervix. A randomized double-blind study
Journal Article · Wed Nov 30 23:00:00 EST 1983 · Am. J. Obstet. Gynecol.; (United States) · OSTI ID:6904971